Literature DB >> 21280133

Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

Andreas Kuglstatter1, April Wong, Stan Tsing, Simon W Lee, Yan Lou, Armando G Villaseñor, J Michael Bradshaw, David Shaw, Jim W Barnett, Michelle F Browner.   

Abstract

Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases. We have determined the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chemical classes. Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop. The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homology 2-kinase domain linker. Two novel activation loop conformations and an atypical DFG conformation are observed representing unique inactive states of BTK. Two regions within the activation loop are shown to structurally transform between 3(10)- and α-helices, one of which collapses into the adenosine-5'-triphosphate binding pocket. The first crystal structure of a Tec kinase family member in the pharmacologically important DFG-out conformation and bound to a type II kinase inhibitor is described. The different protein conformations observed provide insights into the structural flexibility of BTK, the molecular basis of its regulation, and the structure-based design of specific inhibitors.
Copyright © 2010 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21280133      PMCID: PMC3048427          DOI: 10.1002/pro.575

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  22 in total

1.  Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.

Authors:  C Mao; M Zhou; F M Uckun
Journal:  J Biol Chem       Date:  2001-08-29       Impact factor: 5.157

Review 2.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

Review 3.  Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

Authors:  Jessica M Lindvall; K Emelie M Blomberg; Jouni Väliaho; Leonardo Vargas; Juhana E Heinonen; Anna Berglöf; Abdalla J Mohamed; Beston F Nore; Mauno Vihinen; C I Edvard Smith
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

4.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Mark C Genovese; Theresa K Musser; Elliott B Grossbard; Daniel B Magilavy
Journal:  N Engl J Med       Date:  2010-09-22       Impact factor: 91.245

5.  Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.

Authors:  Marc D Jacobs; Paul R Caron; Brian J Hare
Journal:  Proteins       Date:  2008-03

6.  A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.

Authors:  Peter Norman
Journal:  Expert Opin Ther Pat       Date:  2009-10       Impact factor: 6.674

Review 7.  Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.

Authors:  Fatih M Uckun; Sanjive Qazi
Journal:  Expert Opin Ther Pat       Date:  2010-09-10       Impact factor: 6.674

8.  Activation mechanism and steady state kinetics of Bruton's tyrosine kinase.

Authors:  Marie Dinh; Dorit Grunberger; Hoangdung Ho; Stan Y Tsing; David Shaw; Simon Lee; Jim Barnett; Ronald J Hill; David C Swinney; J Michael Bradshaw
Journal:  J Biol Chem       Date:  2007-01-30       Impact factor: 5.157

Review 9.  Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.

Authors:  C Brunner; B Müller; T Wirth
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

Review 10.  Bruton's tyrosine kinase as a drug discovery target.

Authors:  Zhengying Pan
Journal:  Drug News Perspect       Date:  2008-09
View more
  12 in total

1.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

Review 2.  'Black sheep' that don't leave the double-stranded RNA-binding domain fold.

Authors:  Michael L Gleghorn; Lynne E Maquat
Journal:  Trends Biochem Sci       Date:  2014-06-19       Impact factor: 13.807

3.  Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.

Authors:  Ruibin Liu; Shaoqi Zhan; Ye Che; Jana Shen
Journal:  J Med Chem       Date:  2021-10-14       Impact factor: 7.446

4.  Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.

Authors:  R S K Vijayan; Peng He; Vivek Modi; Krisna C Duong-Ly; Haiching Ma; Jeffrey R Peterson; Roland L Dunbrack; Ronald M Levy
Journal:  J Med Chem       Date:  2014-12-12       Impact factor: 7.446

5.  Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

Authors:  Elizabeth B Rex; Suzie Kim; Jake Wiener; Navin L Rao; Marcos E Milla; Daniel DiSepio
Journal:  J Biomol Screen       Date:  2015-05-06

6.  Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor.

Authors:  W Guo; R Liu; G Bhardwaj; J C Yang; C Changou; A-H Ma; A Mazloom; S Chintapalli; K Xiao; W Xiao; P Kumaresan; E Sanchez; C-T Yeh; C P Evans; R Patterson; K S Lam; H-J Kung
Journal:  Cell Death Dis       Date:  2014-09-04       Impact factor: 8.469

7.  Prolonged and tunable residence time using reversible covalent kinase inhibitors.

Authors:  J Michael Bradshaw; Jesse M McFarland; Ville O Paavilainen; Angelina Bisconte; Danny Tam; Vernon T Phan; Sergei Romanov; David Finkle; Jin Shu; Vaishali Patel; Tony Ton; Xiaoyan Li; David G Loughhead; Philip A Nunn; Dane E Karr; Mary E Gerritsen; Jens Oliver Funk; Timothy D Owens; Erik Verner; Ken A Brameld; Ronald J Hill; David M Goldstein; Jack Taunton
Journal:  Nat Chem Biol       Date:  2015-05-25       Impact factor: 15.040

8.  Millisecond dynamics of BTK reveal kinome-wide conformational plasticity within the apo kinase domain.

Authors:  Mohammad M Sultan; Rajiah Aldrin Denny; Ray Unwalla; Frank Lovering; Vijay S Pande
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

9.  Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.

Authors:  Hong Ma; Sanjive Qazi; Zahide Ozer; Jian Zhang; Rita Ishkhanian; Fatih M Uckun
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Structure-functional prediction and analysis of cancer mutation effects in protein kinases.

Authors:  Anshuman Dixit; Gennady M Verkhivker
Journal:  Comput Math Methods Med       Date:  2014-04-08       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.